Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1G93A Mice and Nonhuman Primates

Human Gene Therapy

Volumn 27, Issue 1, 2016, Pages 19-31

  Borel, Florie ^a   Gernoux, Gwladys ^a   Cardozo, Brynn ^a   Metterville, Jake P ^a   Toro Cabreja, Gabriela C ^a   Song, Lina ^a   Su, Qin ^a   Gao, Guang Ping ^a   ElMallah, Mai K ^a   Brown, Robert H ^a   Mueller, Christian ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; SOD1 PROTEIN, HUMAN; SOD1 PROTEIN, MOUSE; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; DEPENDOPARVOVIRUS; DISEASE MODEL; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HUMAN; MOUSE; MUTATION; PATHOLOGY;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE SILENCING; HUMANS; MICE; MUTATION; SUPEROXIDE DISMUTASE; SUPEROXIDE DISMUTASE-1;

EID: 84955240380     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2015.122     Document Type: Article

References (53)

1. McGuire V, Longstreth WT Jr., Koepsell TD, et al. Incidence of amyotrophic lateral sclerosis in three counties in western Washington state. Neurology 1996;47:571-573.
2. Sorenson EJ, Stalker AP, Kurland LT, et al. Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998. Neurology 2002;59: 280-282.
3. Logroscino G, Traynor BJ, Hardiman O, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 2010;81:385-390.
4. Miller RG, Mitchell JD, Lyon M, et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4:191-206.
5. Rosen DR. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;364:362.
6. Prudencio M, Hart PJ, Borchelt DR, et al. Variation in aggregation propensities among ALS-associated variants of SOD1: correlation to human disease. Hum Mol Genet 2009;18:3217-3226.
7. Hetz C, Thielen P, Matus S, et al. XBP-1 deficiency in the nervous system protects against amyotrophic lateral sclerosis by increasing autophagy. Genes Dev 2009;23:2294-2306.
8. Nishitoh H, Kadowaki H, Nagai A, et al. ALSlinked mutant SOD1 induces ER stress-and ASK1-dependent motor neuron death by targeting Derlin-1. Genes Dev 2008;22:1451-1464.
9. Pickles S, Destroismaisons L, Peyrard SL, et al. Mitochondrial damage revealed by immunoselection for ALS-linked misfolded SOD1. Hum Mol Genet 2013;22:3947-3959.
10. van Zundert B, Izaurieta P, Fritz E, et al. Early pathogenesis in the adult-onset neurodegenerative disease amyotrophic lateral sclerosis. J Cell Biochem 2012;113:3301-3312.
11. Song Y, Nagy M, Ni W, et al. Molecular chaperone Hsp110 rescues a vesicle transport defect produced by an ALS-associated mutant SOD1 protein in squid axoplasm. Proc Natl Acad Sci U S A 2013;110:5428-5433.
12. Sundaramoorthy V, Walker AK, Yerbury J, et al. Extracellular wildtype and mutant SOD1 induces ER-Golgi pathology characteristic of amyotrophic lateral sclerosis in neuronal cells. Cell Mol Life Sci 2013;70:4181-4195.
13. Re DB, Le Verche V, Yu C, et al. Necroptosis drives motor neuron death in models of both sporadic and familial ALS. Neuron 2014;81: 1001-1008.
14. Munch C, O'Brien J, Bertolotti A. Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proc Natl Acad Sci U S A 2011;108:3548-3553.
15. Bosco DA, Morfini G, Karabacak NM, et al. Wildtype and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci 2010;13:1396-1403.
16. Maxwell MM, Pasinelli P, Kazantsev AG, et al. RNA interference-mediated silencing of mutant superoxide dismutase rescues cyclosporin Ainduced death in cultured neuroblastoma cells. Proc Natl Acad Sci U S A 2004;101:3178-3183.
17. Xia X, Zhou H, Huang Y, et al. Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo. Neurobiol Disease 2006;23:578-586.
18. Smith RA, Miller TM, Yamanaka K, et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 2006;116: 2290-2296.
19. Ralph GS, Radcliffe PA, Day DM, et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 2005;11:429-433.
20. Raoul C, Abbas-Terki T, Bensadoun JC, et al. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 2005;11:423-428.
21. Foust KD, Salazar DL, Likhite S, et al. Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol Ther 2013;21:2148-2159.
22. Thomsen GM, Gowing G, Latter J, et al. Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex. J Neurosci 2014;34:15587-15600.
23. Dirren E, Aebischer J, Rochat C, et al. SOD1 silencing in motoneurons or glia rescues neuromuscular function in ALS mice. Ann Clin Transl Neurol 2015;2:167-184.
24. Wang H, Yang B, Qiu L, et al. Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis. Hum Mol Genet 2014;23:668-681.
25. Zerah M, Piguet F, Colle MA, et al. Intracerebral gene therapy using AAVrh. 10-hARSA recombinant vector to treat patients with early-onset forms of metachromatic leukodystrophy: Preclinical feasibility and safety assessments in nonhuman primates. Hum Gene Ther Clincal Dev 2015;26:113-124.
26. Wright PD, Wightman N, Huang M, et al. A highthroughput screen to identify inhibitors of SOD1 transcription. Front Biosci 2012;4:2801-2808.
27. ElMallah MK, Falk DJ, Lane MA, et al. Retrograde gene delivery to hypoglossal motoneurons using adeno-associated virus serotype 9. Hum Gene Ther Methods 2012;23:148-156.
28. Elmallah MK, Falk DJ, Nayak S, et al. Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice. Mol Ther 2014;22:702-712.
29. ElMallah MK, Pagliardini S, Turner SM, et al. Stimulation of respiratory motor output and ventilation in a murine model of Pompe disease by ampakines. Am J Respir Cell Mol Biol 2015;53:326-335.
30. Drorbaugh JE, Fenn WO. A barometric method for measuring ventilation in newborn infants. Pediatrics 1955;16:81-87.
31. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001;25:402-408.
32. Mansfield K. Marmoset models commonly used in biomedical research. Comp Med 2003;53: 383-392.
33. Okano H, Mitra P. Brain-mapping projects using the common marmoset. Neurosci Res 2015;93:3-7.
34. Sasaki E, Suemizu H, Shimada A, et al. Generation of transgenic non-human primates with germline transmission. Nature 2009;459:523-527.
35. Kendall AL, Rayment FD, Torres EM, et al. Functional integration of striatal allografts in a primate model of Huntington's disease. Nat Med 1998;4:727-729.
36. Ando K, Maeda J, Inaji M, et al. Neurobehavioral protection by single dose l-deprenyl against MPTP-induced parkinsonism in common marmosets. Psychopharmacology 2008;195:509-516.
37. Gnanalingham KK, Smith LA, Hunter AJ, et al. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: An autoradiographic study. Synapse 1993;14:184-194.
38. Baker HF, Ridley RM, Duchen LW, et al. Experimental induction of beta-amyloid plaques and cerebral angiopathy in primates. Ann N Y Acad Sci 1993;695:228-231.
39. Maclean CJ, Baker HF, Ridley RM, et al. Naturally occurring and experimentally induced betaamyloid deposits in the brains of marmosets (Callithrix jacchus). J Neural Transm 2000;107: 799-814.
40. Gray SJ, Nagabhushan Kalburgi S, McCown TJ, et al. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther 2013;20:450-459.
41. Tankersley CG, Haenggeli C, Rothstein JD. Respiratory impairment in a mouse model of amyotrophic lateral sclerosis. J Appl Physiol 2007;102: 926-932.
42. McBride JL, Boudreau RL, Harper SQ, et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A 2008;105:5868-5873.
43. Borel F, van LR, Koornneef A, et al. In vivo knockdown of multidrug resistance transporters ABCC1 and ABCC2 by AAV-delivered shRNAs and by artificial miRNAs. J RNAiGene Silencing 2011;7: 434-442.
44. Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/ short hairpin RNA pathways. Nature 2006;441: 537-541.
45. Boudreau RL, Martins I, Davidson BL. Artificial microRNAs as siRNA shuttles: Improved safety as compared to shRNAs in vitro and in vivo. MolTher 2009;17:169-175.
46. Ehlert EM, Eggers R, Niclou SP, et al. Cellular toxicity following application of adeno-associated viral vector-mediated RNA interference in the nervous system. BMC Neurosci 2010;11:20.
47. Khodr CE, Sapru MK, Pedapati J, et al. An alphasynuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons. Brain Res 2011;1395:94-107.
48. Martin JN, Wolken N, Brown T, et al. Lethal toxicity caused by expression of shRNA in the mouse striatum: Implications for therapeutic design. Gene Ther 2011;18:666-673.
49. Ulusoy A, Sahin G, Bjorklund T, et al. Dose optimization for long-term rAAV-mediated RNA interference in the nigrostriatal projection neurons. Mol Ther 2009;17:1574-1584.
50. Foust KD, Wang X, McGovern VL, et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 2010;28:271-274.
51. Samaranch L, Salegio EA, San Sebastian W, et al. Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum Gene Ther 2012;23: 382-389.
52. Thwaite R, Pages G, Chillon M, et al. AAVrh. 10 immunogenicity in mice and humans. Relevance of antibody cross-reactivity in human gene therapy. Gene Ther 2015;22:196-201.
53. Meyer K, Ferraiuolo L, Schmelzer L, et al. Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: A dose-response study in mice and nonhuman primates. Mol Ther 2015;23:477-487.